Knight Therapeutics Inc.

Knight Therapeutics Inc. is a pan-American (excluding the U.S.) specialty pharmaceutical company headquartered in Montreal, Quebec, Canada. Its core business revolves around acquiring, in-licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals, as well as consumer health products and medical devices. The company's mission is to build a leading specialty pharmaceutical presence across Canada and Latin America by delivering innovative and branded generic products to address unmet medical needs in these markets.

Knight Therapeutics manages a diverse portfolio of over 100 products, focusing on key therapeutic areas such as oncology, hematology, infectious diseases, neurology, women's health, gastrointestinal conditions, pain, and ophthalmology. The company operates in Canada and across more than 10 countries in Latin America, leveraging strategic partnerships to bring specialized treatments to these regions. Notable products in its portfolio or pipeline include Movantik, Impavido, Jornay PM® for ADHD, Crexont® for Parkinson's disease, MYFEMBREE®, ORGOVYX® for prostate cancer, and MINJUVI® for lymphoma.

Samira Sakhia serves as the President and Chief Executive Officer, with Jonathan Ross Goodman as the Executive Chairman. Knight Therapeutics reported strong financial results for the fiscal year ended December 31, 2025, with revenues reaching $450.088 million, marking a 21% increase over the previous year. The company has provided revenue guidance of $490 million to $510 million for 2026, driven by recent product launches and strategic acquisitions, such as the Paladin business in June 2025, which has further strengthened its Canadian operations.